COP1 Polyklonaler Antikörper

COP1 Polyklonal Antikörper für IHC, WB,ELISA

Wirt / Isotyp

Kaninchen / IgG

Getestete Reaktivität

human, Maus, Ratte

Anwendung

WB, IHC,ELISA

Konjugation

Unkonjugiert

Publikationen

1

Kat-Nr. : 13542-1-AP

Synonyme

COP1, hCOP1, RFWD2, RING finger protein 200, RNF200

---

Galerie der Validierungsdaten

• 

  WB analysis of mouse heart using 13542-1-AP

  mouse heart tissue were subjected to SDS PAGE followed by western blot with 13542-1-AP (COP1 antibody) at dilution of 1:600 incubated at room temperature for 1.5 hours.

• 

  IHC staining of human osteosarcoma using 13542-1-AP

  Immunohistochemical analysis of paraffin-embedded human osteosarcoma tissue slide using 13542-1-AP (COP1 Antibody) at dilution of 1:200 (under 10x lens). Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).

• 

  IHC staining of human osteosarcoma using 13542-1-AP

  Immunohistochemical analysis of paraffin-embedded human osteosarcoma tissue slide using 13542-1-AP (COP1 Antibody) at dilution of 1:200 (under 40x lens). Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).

• 

  IHC staining of human osteosarcoma using 13542-1-AP

  Immunohistochemical analysis of paraffin-embedded human osteosarcoma using 13542-1-AP (COP1 antibody) at dilution of 1:100 (under 10x lens).

• 

  IHC staining of human osteosarcoma using 13542-1-AP

  Immunohistochemical analysis of paraffin-embedded human osteosarcoma using 13542-1-AP (COP1 antibody) at dilution of 1:100 (under 40x lens).

---

Geprüfte Anwendungen

• Erfolgreiche Detektion in WB: humanes Herzgewebe, Mausherzgewebe
• Erfolgreiche Detektion in IHC: humanes Osteosarkomgewebe; Hinweis: Antigendemaskierung mit TE-Puffer pH 9,0 empfohlen. (*) Wahlweise kann die Antigendemaskierung auch mit Citratpuffer pH 6,0 erfolgen.

Empfohlene Verdünnung

• Western Blot (WB): WB : 1:500-1:1000
• Immunhistochemie (IHC): IHC : 1:50-1:500

It is recommended that this reagent should be titrated in each testing system to obtain optimal results.

Sample-dependent, check data in validation data gallery

Veröffentlichte Anwendungen

• KD/KO: See 1 publications below
• WB: See 1 publications below

Produktinformation

13542-1-AP bindet in WB, IHC,ELISA COP1 und zeigt Reaktivität mit human, Maus, Ratten

• Getestete Reaktivität: human, Maus, Ratte
• In Publikationen genannte Reaktivität: human
• Wirt / Isotyp: Kaninchen / IgG
• Klonalität: Polyklonal
• Typ: Antikörper
• Immunogen: COP1 fusion protein Ag4484
• Vollständiger Name: ring finger and WD repeat domain 2
• Berechnetes Molekulargewicht: 731 aa, 80 kDa
• Beobachtetes Molekulargewicht: 90 kDa
• GenBank-Zugangsnummer: BC039723
• Gene symbol: RFWD2
• Gene ID (NCBI): 64326
• Konjugation: Unkonjugiert
• Form: Liquid
• Reinigungsmethode: Antigen-Affinitätsreinigung
• Lagerungspuffer: PBS mit 0.02% Natriumazid und 50% Glycerin pH 7.3.
• Lagerungsbedingungen: Bei -20°C lagern. Nach dem Versand ein Jahr lang stabil Aliquotieren ist bei -20^oC Lagerung nicht notwendig. 20ul Größen enthalten 0,1% BSA.

Hintergrundinformationen

COP1 is also named as RFWD2, RNF200 and belongs to the COP1 family. It is a ubiquitin ligase that targets key regulators for degradation, and DET1 complexes with COP10 and DDB1, which is proposed to aid in COP1-mediated degradation (PMID:22705257). The endogenous COP1 is localized predominantly in the nucleus, but small amount may also be present in the cytosol. Within the nucleus, COP1 is present in both the nucleoplasm (NP) and the nuclear envelope (NE) fractions, although COP1 is more enriched in the nucleoplasm (PMID:12466024). Two of the COP1 isoforms identified by RNA-seq analysis predicted the size of two proteins detected by the antibody for COP1, a 75 kDa band, corresponding to the longer isoform, and a 50 kDa band corresponding to the shorter isoform. (PMID:24714719). It has been shown that COP1 forms dimerization through its coiled-coil region.

Publikationen

Species	Application	Title
human	WB	Cancer Lett; Primate-specific miR-944 activates p53-dependent tumor suppression in human colorectal cancers.; Authors - Yoon-Jin Kim ; KD Validated